Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leukemia
{{output}}
Aims: This study aims to quantify costs and healthcare resource utilization (HCRU) associated with switching from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia in pediatr... ...
